(-0.14%) 5 205.50 points
(-0.10%) 39 157 points
(-0.22%) 18 147 points
(0.51%) $79.39
(0.05%) $2.19
(0.15%) $2 325.80
(1.03%) $27.89
(0.76%) $992.10
(0.07%) $0.931
(0.13%) $10.90
(0.05%) $0.801
(0.28%) $92.00
Live Chart Being Loaded With Signals
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally...
Stats | |
---|---|
Today's Volume | 54 842.00 |
Average Volume | 452 119 |
Market Cap | 76.87B |
EPS | INR0 ( 2024-01-29 ) |
Next earnings date | ( INR0 ) 2024-05-23 |
Last Dividend | INR1.500 ( 2023-08-04 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -49.82 |
ATR14 | INR1.032 (0.12%) |
Volume Correlation
Strides Pharma Science Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Strides Pharma Science Correlation - Currency/Commodity
Strides Pharma Science Financials
Annual | 2022 |
Revenue: | INR36.88B |
Gross Profit: | INR20.62B (55.89 %) |
EPS: | INR-25.63 |
FY | 2022 |
Revenue: | INR36.88B |
Gross Profit: | INR20.62B (55.89 %) |
EPS: | INR-25.63 |
FY | 2022 |
Revenue: | INR30.22B |
Gross Profit: | INR14.39B (47.61 %) |
EPS: | INR-52.84 |
FY | 2021 |
Revenue: | INR32.51B |
Gross Profit: | INR18.42B (56.67 %) |
EPS: | INR29.96 |
Financial Reports:
No articles found.
Strides Pharma Science Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR1.500 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR1.500 | 2010-05-21 |
Last Dividend | INR1.500 | 2023-08-04 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR651.50 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 0.96 | -- |
Div. Sustainability Score | 0.216 | |
Div.Growth Potential Score | 1.264 | |
Div. Directional Score | 0.740 | -- |
Year | Amount | Yield |
---|---|---|
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.00 | 0.36% |
2019 | INR15.00 | 3.22% |
2020 | INR2.00 | 0.55% |
2021 | INR2.50 | 0.28% |
2022 | INR0 | 0.00% |
2023 | INR1.500 | 0.42% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TCPLPACK.NS | Dividend Junior | 2023-07-27 | Annually | 7 | 1.08% | |
OBEROIRLTY.NS | Dividend Junior | 2023-06-21 | Sporadic | 14 | 0.19% | |
INFOBEAN.NS | Dividend Junior | 2023-07-21 | Annually | 7 | 0.37% | |
CONCOR.NS | Dividend Knight | 2023-09-18 | Semi-Annually | 23 | 0.89% | |
SESHAPAPER.NS | Dividend Knight | 2023-06-07 | Annually | 23 | 1.14% | |
MALLCOM.NS | Dividend Junior | 2023-09-04 | Annually | 3 | 0.20% | |
GOKEX.NS | Dividend Junior | 2023-09-13 | Sporadic | 20 | 0.07% | |
AUTOAXLES.NS | Dividend Junior | 2023-07-27 | Annually | 22 | 0.72% | |
TRIL.NS | Dividend Junior | 2023-07-27 | Sporadic | 17 | 0.22% | |
PIIND.NS | Dividend Knight | 2023-08-10 | Semi-Annually | 14 | 0.18% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0259 | 1.500 | -0.519 | -0.778 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.0487 | 1.500 | -1.652 | -2.48 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.132 | 1.000 | -0.692 | -0.692 | [3 - 30] |
operatingCashFlowPerShareTTM | 37.52 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 37.52 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.589 | 1.000 | 3.52 | 3.52 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0901 | 1.000 | -0.198 | -0.198 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.216 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -75.74 | 1.000 | -7.75 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0487 | 2.50 | -1.062 | -2.48 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 37.52 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.177 | 1.500 | 5.59 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 37.52 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0868 | 1.000 | -0.330 | 0 | [0.1 - 0.5] |
Total Score | 1.264 |
Strides Pharma Science
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators